In addition to that, the use of multigene assays to assess the intrinsic molecular characteristics of ER-positive, HER2-negative tumors in early-stage breast cancer patients has led to a more precise risk stratification for recurrence at the individual patient level. The gene discussed is ERBB2; the disease is breast cancer.